Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study - Concepedia

Concepedia

Publication | Open Access

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

DOI Full Paper Access

348

Citations

36

References

2013

Year

André Goy, Rajni Sinha, Michael E. Williams, Sevgi Kalayoğlu Beşışık, Johannes Drach, Radhakrishnan Ramchandren, Lei Zhang, Sherri Cicero, Tommy Fu, Thomas E. Witzig

Journal of Clinical Oncology

Abstract

The MCL-001 study demonstrated durable efficacy of lenalidomide with a predictable safety profile in heavily pretreated patients with MCL who had all relapsed or progressed after or were refractory to bortezomib.

References

	Year	Citations

Page 1